Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach

Didik Setiawan; Nikolaos Kotsopoulos; Jan C Wilschut; Maarten J Postma; Mark P Connolly

doi:10.1371/journal.pone.0160707

Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach

Didik Setiawan^*, Nikolaos Kotsopoulos, Jan C Wilschut, Maarten J Postma, Mark P Connolly

^*Corresponding author for this work

Research output: Contribution to journal › Article › Academic › peer-review

11 Citations (Scopus)

326 Downloads (Pure)

Abstract

Background

Cervical cancer poses a substantial burden in terms of morbidity, mortality, and economic losses, especially in low/middle-income countries. HPV vaccination and/or cervical cancer screening among females may reduce the burden of HPV-related diseases, including cervical cancer. However, limited funds may impede the implementation of population-based programmes. Governmental investments in the prevention of infectious disease may have broader economic and fiscal benefits, which are not accounted in conventional economic analyses. This study estimates the broader economic and fiscal impacts of implementing HPV vaccination and/or cervical cancer screening in Indonesia from the perspective of the government.

Methods

A government-perspective quantitative analytic framework was applied to assess the Net Present Value (NPV) of investment on cervical cancer prevention strategies including HPV vaccination, cervical screening and its combination in Indonesia. All monetary values were presented in International Dollars (I$).

Results

Based on a cohort of 10,000,000 Indonesian 12-year-old females, it was estimated that HPV vaccination and/or cervical cancer screening result in a positive NPV for the Indonesian government. The combination of cervical screening and HPV vaccination generated a substantial reduction of cervical cancer incidence and HPV-related mortality of 87,862 and 19,359, respectively. It was estimated that HPV vaccination in combination with cervical screening is the most favorable option for cervical cancer prevention (NPV I $2.031.786.000), followed by HPV vaccination alone (NPV I$1.860.783.000) and cervical screening alone (NPV I$375.244.000).

Conclusion

In addition to clinical benefits, investing in HPV vaccination and cervical screening may yield considerable fiscal benefits for the Indonesian governments due to lifelong benefits resulting from reduction of cervical cancer-related morbidity and mortality.

Original language	English
Article number	e0160707
Number of pages	12
Journal	PLoS ONE
Volume	11
Issue number	8
DOIs	https://doi.org/10.1371/journal.pone.0160707
Publication status	Published - 4-Aug-2016

Keywords

CERVICAL-CANCER PREVENTION
HUMAN-PAPILLOMAVIRUS VACCINATION
COST-EFFECTIVENESS
AS04-ADJUVANTED VACCINE
QUADRIVALENT VACCINE
THAILAND
HEALTH
TRIAL
STRATEGIES
MORTALITY

Access to Document

10.1371/journal.pone.0160707Licence: CC BY

Assessment of the Broader Economic Consequences of HPV Prevention from a Government-PerspectiveFinal publisher's version, 492 KBLicence: CC BY

Handle.net

Persistent link

Assessment of the broader economic consequences of HPV prevention from a government-perspective: a fiscal analytic approach
Setiawan, D. (Contributor), Kotsopoulos, N. (Contributor), Wilschut, J. (Contributor), Postma, M. J. (Contributor) & Connolly, M. (Contributor), Dryad Digital Repository, 27-Jul-2017
DOI: 10.5061/dryad.9n34t/1
Dataset
Data from: Assessment of the broader economic consequences of HPV prevention from a government-perspective: a fiscal analytic approach
Setiawan, D. (Creator), Kotsopoulos, N. (Creator), Wilschut, J. (Creator), Postma, M. (Creator) & Connolly, M. (Creator), University of Groningen, 13-Sept-2016
DOI: 10.5061/dryad.9n34t
Dataset

Cite this

@article{445490f68b504fdf90396e147a8127b4,

title = "Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach",

abstract = "BackgroundCervical cancer poses a substantial burden in terms of morbidity, mortality, and economic losses, especially in low/middle-income countries. HPV vaccination and/or cervical cancer screening among females may reduce the burden of HPV-related diseases, including cervical cancer. However, limited funds may impede the implementation of population-based programmes. Governmental investments in the prevention of infectious disease may have broader economic and fiscal benefits, which are not accounted in conventional economic analyses. This study estimates the broader economic and fiscal impacts of implementing HPV vaccination and/or cervical cancer screening in Indonesia from the perspective of the government.MethodsA government-perspective quantitative analytic framework was applied to assess the Net Present Value (NPV) of investment on cervical cancer prevention strategies including HPV vaccination, cervical screening and its combination in Indonesia. All monetary values were presented in International Dollars (I$).ResultsBased on a cohort of 10,000,000 Indonesian 12-year-old females, it was estimated that HPV vaccination and/or cervical cancer screening result in a positive NPV for the Indonesian government. The combination of cervical screening and HPV vaccination generated a substantial reduction of cervical cancer incidence and HPV-related mortality of 87,862 and 19,359, respectively. It was estimated that HPV vaccination in combination with cervical screening is the most favorable option for cervical cancer prevention (NPV I $2.031.786.000), followed by HPV vaccination alone (NPV I$1.860.783.000) and cervical screening alone (NPV I$375.244.000).ConclusionIn addition to clinical benefits, investing in HPV vaccination and cervical screening may yield considerable fiscal benefits for the Indonesian governments due to lifelong benefits resulting from reduction of cervical cancer-related morbidity and mortality.",

keywords = "CERVICAL-CANCER PREVENTION, HUMAN-PAPILLOMAVIRUS VACCINATION, COST-EFFECTIVENESS, AS04-ADJUVANTED VACCINE, QUADRIVALENT VACCINE, THAILAND, HEALTH, TRIAL, STRATEGIES, MORTALITY",

author = "Didik Setiawan and Nikolaos Kotsopoulos and Wilschut, {Jan C} and Postma, {Maarten J} and Connolly, {Mark P}",

year = "2016",

month = aug,

day = "4",

doi = "10.1371/journal.pone.0160707",

language = "English",

volume = "11",

journal = "PLoS ONE",

issn = "1932-6203",

publisher = "PUBLIC LIBRARY SCIENCE",

number = "8",

}

TY - JOUR

T1 - Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective

T2 - A Fiscal Analytic Approach

AU - Setiawan, Didik

AU - Kotsopoulos, Nikolaos

AU - Wilschut, Jan C

AU - Postma, Maarten J

AU - Connolly, Mark P

PY - 2016/8/4

Y1 - 2016/8/4

N2 - BackgroundCervical cancer poses a substantial burden in terms of morbidity, mortality, and economic losses, especially in low/middle-income countries. HPV vaccination and/or cervical cancer screening among females may reduce the burden of HPV-related diseases, including cervical cancer. However, limited funds may impede the implementation of population-based programmes. Governmental investments in the prevention of infectious disease may have broader economic and fiscal benefits, which are not accounted in conventional economic analyses. This study estimates the broader economic and fiscal impacts of implementing HPV vaccination and/or cervical cancer screening in Indonesia from the perspective of the government.MethodsA government-perspective quantitative analytic framework was applied to assess the Net Present Value (NPV) of investment on cervical cancer prevention strategies including HPV vaccination, cervical screening and its combination in Indonesia. All monetary values were presented in International Dollars (I$).ResultsBased on a cohort of 10,000,000 Indonesian 12-year-old females, it was estimated that HPV vaccination and/or cervical cancer screening result in a positive NPV for the Indonesian government. The combination of cervical screening and HPV vaccination generated a substantial reduction of cervical cancer incidence and HPV-related mortality of 87,862 and 19,359, respectively. It was estimated that HPV vaccination in combination with cervical screening is the most favorable option for cervical cancer prevention (NPV I $2.031.786.000), followed by HPV vaccination alone (NPV I$1.860.783.000) and cervical screening alone (NPV I$375.244.000).ConclusionIn addition to clinical benefits, investing in HPV vaccination and cervical screening may yield considerable fiscal benefits for the Indonesian governments due to lifelong benefits resulting from reduction of cervical cancer-related morbidity and mortality.

AB - BackgroundCervical cancer poses a substantial burden in terms of morbidity, mortality, and economic losses, especially in low/middle-income countries. HPV vaccination and/or cervical cancer screening among females may reduce the burden of HPV-related diseases, including cervical cancer. However, limited funds may impede the implementation of population-based programmes. Governmental investments in the prevention of infectious disease may have broader economic and fiscal benefits, which are not accounted in conventional economic analyses. This study estimates the broader economic and fiscal impacts of implementing HPV vaccination and/or cervical cancer screening in Indonesia from the perspective of the government.MethodsA government-perspective quantitative analytic framework was applied to assess the Net Present Value (NPV) of investment on cervical cancer prevention strategies including HPV vaccination, cervical screening and its combination in Indonesia. All monetary values were presented in International Dollars (I$).ResultsBased on a cohort of 10,000,000 Indonesian 12-year-old females, it was estimated that HPV vaccination and/or cervical cancer screening result in a positive NPV for the Indonesian government. The combination of cervical screening and HPV vaccination generated a substantial reduction of cervical cancer incidence and HPV-related mortality of 87,862 and 19,359, respectively. It was estimated that HPV vaccination in combination with cervical screening is the most favorable option for cervical cancer prevention (NPV I $2.031.786.000), followed by HPV vaccination alone (NPV I$1.860.783.000) and cervical screening alone (NPV I$375.244.000).ConclusionIn addition to clinical benefits, investing in HPV vaccination and cervical screening may yield considerable fiscal benefits for the Indonesian governments due to lifelong benefits resulting from reduction of cervical cancer-related morbidity and mortality.

KW - CERVICAL-CANCER PREVENTION

KW - HUMAN-PAPILLOMAVIRUS VACCINATION

KW - COST-EFFECTIVENESS

KW - AS04-ADJUVANTED VACCINE

KW - QUADRIVALENT VACCINE

KW - THAILAND

KW - HEALTH

KW - TRIAL

KW - STRATEGIES

KW - MORTALITY

U2 - 10.1371/journal.pone.0160707

DO - 10.1371/journal.pone.0160707

M3 - Article

C2 - 27490258

SN - 1932-6203

VL - 11

JO - PLoS ONE

JF - PLoS ONE

IS - 8

M1 - e0160707

ER -

Assessment of the Broader Economic Consequences of HPV Prevention from a Government-Perspective: A Fiscal Analytic Approach

Abstract

Keywords

Access to Document

Handle.net

Fingerprint

Datasets

Assessment of the broader economic consequences of HPV prevention from a government-perspective: a fiscal analytic approach

Data from: Assessment of the broader economic consequences of HPV prevention from a government-perspective: a fiscal analytic approach

Cite this